Overview

A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

Status:
RECRUITING

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of HSK39297 tablets compared to eculizumab in Patients with PNH who Are Naive to Complement Inhibitor Therapy.

Phase:

PHASE3

Details

Lead Sponsor:

Haisco Pharmaceutical Group Co., Ltd.

Treatments:

eculizumab